TSE:CPH FY2025 EPS Forecast Cut by Leede Financial

Key Points

• Leede Financial has lowered its FY2025 earnings per share (EPS) estimate for Cipher Pharmaceuticals to $0.86, down from $0.87, while the consensus estimate remains at $1.29.
• Cipher Pharmaceuticals' share price opened at C$14.94, with a one-year trading range between C$10.61 and C$19.69.
• The company focuses on specialty pharmaceuticals, offering products in dermatology, hospital care, and out-licensed segments across Canada and the United States.

Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Stock analysts at Leede Financial lowered their FY2025 earnings per share (EPS) estimates for shares of Cipher Pharmaceuticals in a research note issued to investors on Monday, August 11th. Leede Financial analyst D. Loe now anticipates that the company will earn $0.86 per share for the year, down from their prior estimate of $0.87. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals' FY2026 earnings at $0.97 EPS.

Cipher Pharmaceuticals Trading Down 0.7%

CPH opened at C$14.94 on Wednesday. Cipher Pharmaceuticals has a one year low of C$10.61 and a one year high of C$19.69. The company has a market cap of C$268.22 million, a P/E ratio of 16.50 and a beta of 1.20. The company has a debt-to-equity ratio of 41.22, a quick ratio of 2.67 and a current ratio of 2.00. The business's 50-day simple moving average is C$12.95 and its 200-day simple moving average is C$12.69.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.